<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27913" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Prurigo Nodularis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mullins</surname>
            <given-names>Tessa B.</given-names>
          </name>
          <aff>Lewis Gale Hospital - Montgomery</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Poonam</given-names>
          </name>
          <aff>Goa University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Riley</surname>
            <given-names>Christopher A.</given-names>
          </name>
          <aff>San Antonio Uniformed Services Health Education Consortium</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Syed</surname>
            <given-names>Hasnain A.</given-names>
          </name>
          <aff>Sheikh Zayed Hospital, Lahore</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sonthalia</surname>
            <given-names>Sidharth</given-names>
          </name>
          <aff>SKINNOCENCE: The Skin Clinic</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tessa Mullins declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Poonam Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Christopher Riley declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hasnain Syed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sidharth Sonthalia declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27913.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Prurigo nodularis (PN) is a chronic skin disorder characterized by multiple, firm, flesh-to-pink colored papules, plaques, and nodules predominantly found on the extensor surfaces of the extremities. These lesions are intensely&#x000a0;pruritic and&#x000a0;manifest across diverse age groups. PN often coexists with other cutaneous hypersensitivity disorders, such as atopic dermatitis or chronic pruritus, making its diagnosis primarily clinical yet necessitating differentiation from similar conditions like lichen simplex chronicus&#x000a0;or&#x000a0;hypertrophic lichen planus. Dermoscopy and histopathology serve as crucial tools for diagnostic confirmation in challenging cases.</p>
        <p>Management of PN encompasses a multifaceted approach involving potent antipruritics, immunomodulators, and neuromodulators tailored to patients' specific needs.&#x000a0;Long-term therapy is often necessary as PN tends to be refractory to conventional treatments, emphasizing the importance of patient education, counseling, and compliance.&#x000a0;This activity reviews the evaluation and comprehensive management strategies for PN, highlighting the role of the interprofessional team in caring for patients with this debilitating skin condition, considering both its physical and psychological ramifications.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of prurigo nodularis (PN), including its association with diverse cutaneous hypersensitivity disorders like atopic dermatitis, chronic pruritus, and other potential underlying conditions.</p></list-item><list-item><p>Evaluate PN lesions through history, examination, and lab testing to confirm diagnosis and differentiate them from other dermatological conditions with similar clinical presentations.&#x000a0;</p></list-item><list-item><p>Determine the treatment plan and management options available for PN based on individual patient needs and the chronic, refractory nature of the condition.&#x000a0;</p></list-item><list-item><p>Collaborate with the interprofessional team to optimize management strategies for improved patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27913&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27913">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27913.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Prurigo nodularis (PN) is a chronic disorder of the skin that is classically seen as multiple, firm, flesh-to-pink-colored nodules commonly located on the extensor surfaces of the extremities. The lesions are&#x000a0;very pruritic, and the condition may occur in any age group. It is commonly associated with another disorder of cutaneous hypersensitivity, such as atopic dermatitis or chronic pruritus of diverse origins. The diagnosis is mainly clinical, although certain conditions may simulate it clinically, warranting differentiation. The condition is associated with significant physical and psychological morbidity and is often refractory to treatments. A wide range of general measures, pharmacological approaches, and psychological therapies may be needed in a patient with advanced PN.<xref ref-type="bibr" rid="article-27913.r1">[1]</xref><xref ref-type="bibr" rid="article-27913.r2">[2]</xref><xref ref-type="bibr" rid="article-27913.r3">[3]</xref><xref ref-type="bibr" rid="article-27913.r4">[4]</xref></p>
      </sec>
      <sec id="article-27913.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The exact etiology of&#x000a0;PN remains poorly understood. Although the role of the unimpeded itch-scratch cycle is uncontested, the exact sequence of events leading to the final clinical picture remains debated.&#x000a0;PN is accompanied by long-standing pruritus and is thought to develop as a reaction to repeated scratching in patients with chronic prurigo of various etiologies, including dermatological, systemic, infectious, and neuropsychiatric.<xref ref-type="bibr" rid="article-27913.r5">[5]</xref><xref ref-type="bibr" rid="article-27913.r6">[6]</xref>&#x000a0;Anecdotal data suggest a causative role or association of infectious agents&#x000a0;such as hepatitis C, <italic toggle="yes">Helicobacter pylori, Strongyloides stercoralis, mycobacteria,&#x000a0;</italic>and HIV.<xref ref-type="bibr" rid="article-27913.r7">[7]</xref><xref ref-type="bibr" rid="article-27913.r8">[8]</xref>&#x000a0;</p>
        <p>An increase in the number of sensory structures of the epidermis (Merkel cells) and dermis (papillary dermal nerves) is encountered in PN lesions.<xref ref-type="bibr" rid="article-27913.r9">[9]</xref>&#x000a0;This neural alteration is typical of PN and not seen in lichen simplex chronicus or neurodermatitis.&#x000a0;The density of mast cells and neutrophils is also increased in PN, although there seems to be no increase in their degranulation products. In contrast,&#x000a0;although the number of eosinophils remains maintained, their products, such as the major basic protein and eosinophil-derived neurotoxin, show higher than normal levels.</p>
        <p>The pruritus in PN seems to be a result of cutaneous&#x000a0;neurogenic inflammation mediated by various neuropeptides, especially substance P, calcitonin gene&#x02013;related peptide (CGRP),<xref ref-type="bibr" rid="article-27913.r10">[10]</xref>&#x000a0;and&#x000a0;vanilloid receptor subtype 1 (VR-1). The latter binds to capsaicin, rendering it a potential therapeutic topical agent. Individuals with PN also show elevated levels of interleukin 31 (IL-31), a T-cell&#x02013;derived highly prurigogenic cytokine.<xref ref-type="bibr" rid="article-27913.r11">[11]</xref></p>
      </sec>
      <sec id="article-27913.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The exact incidence of&#x000a0;PN is unknown. A majority of patients with&#x000a0;PN present between the ages of 51 and 65 years, although several cases in other age groups have also been described.<xref ref-type="bibr" rid="article-27913.r5">[5]</xref><xref ref-type="bibr" rid="article-27913.r12">[12]</xref>&#x000a0;The disease afflicts both genders; however,&#x000a0;it seems to be more frequent and more intense in females.<xref ref-type="bibr" rid="article-27913.r13">[13]</xref>&#x000a0;Multiple studies have shown that individuals with an atopic predisposition have an earlier age of onset.<xref ref-type="bibr" rid="article-27913.r5">[5]</xref><xref ref-type="bibr" rid="article-27913.r14">[14]</xref><xref ref-type="bibr" rid="article-27913.r15">[15]</xref>&#x000a0;Ethnicity and genetic predisposition seem to play a role since African-Americans are 3 to 4 times more likely to have&#x000a0;PN than white patients.<xref ref-type="bibr" rid="article-27913.r12">[12]</xref>&#x000a0;Other&#x000a0;conditions that have been reported to induce&#x000a0;PN include internal malignancy, renal failure, and psychiatric conditions. In HIV-positive patients,&#x000a0;PN&#x000a0;has been reported to be predictive of advanced immunosuppression.<xref ref-type="bibr" rid="article-27913.r16">[16]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-27913.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of&#x000a0;PN has been controversial.&#x000a0;Chronic or recurrent mechanical trauma or vigorous frictional assault to the skin induces epidermal hyperplasia with resultant thickening of the skin. Repetitive mechanical rubbing&#x000a0;and scratching of the skin result in the formation of plaques and nodules&#x000a0;(often with lichenification)&#x000a0;and also give rise to dyschromic changes&#x000a0;(typically hyperpigmentation). The itching of PN is typically episodic, severe, and uncontrollable; it tends to occur at discrete points that eventually transform into hyperpigmented nodular plaques with excoriations, crusting, and sometimes secondary bacterial infection.</p>
        <p>Immunohistochemical studies have shown increased dermal nerve fibers in the papillary dermis of patients with PN. It has been postulated that the thin, unmyelinated epidermal nerves are the transmitters of severe prurigo. Nerve growth factor (NGF) and its receptor, tyrosine receptor kinase A (TrkA), are overexpressed in PN lesions; both&#x000a0;may also be associated with the increased release and accumulation of neuropeptides, such as substance P and calcitonin gene&#x02013;related peptides.<xref ref-type="bibr" rid="article-27913.r17">[17]</xref>&#x000a0;Interestingly, skin biopsies taken from lesions of PN tend to show&#x000a0;significantly decreased intraepidermal&#x02014;not dermal&#x02014;nerve fiber density. Although this finding has raised doubt about some subclinical small nerve fiber neuropathy contributing to the pathophysiology of PN, recent studies have suggested that&#x000a0;the reduction may be secondary to chronic scratching. This suggestion was confirmed by observing restoration of the intraepidermal&#x000a0;nerve fiber density on complete healing of lesions.<xref ref-type="bibr" rid="article-27913.r18">[18]</xref></p>
        <p>The role of helper T cytokines (T helper 1 [Th1] and T helper 2 [Th2]) has also been studied in the pathogenesis of PN using the signal transducers and activators of transcription (STAT) 1, 3, and 6. In&#x000a0;all but 3 cases, the entire epidermis was stained with anti&#x02013;phosphorylated STAT (pSTAT) 6, a marker for the Th2 cytokines IL-4, IL-5, and IL-13. These findings suggest that Th2 cytokines play a principal role in the pathogenesis of PN.<xref ref-type="bibr" rid="article-27913.r19">[19]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-27913.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>PN lesions under histopathology can show thick orthohyperkeratosis, irregular epidermal hyperplasia, and pseudoepitheliomatous hyperplasia. Focal parakeratosis with irregular acanthosis, diminished nerve fiber density, and a nonspecific dermal infiltrate containing lymphocytes, macrophages, eosinophils, and neutrophils may also be seen.</p>
        <p>Histology can be important in&#x000a0;differentiating PN&#x000a0;from lichen simplex (LS) and hypertrophic lichen planus (HLP). LS&#x000a0;lesions are less likely to have pseudoepitheliomatous hyperplasia or nerve fiber thickening; however, these findings do not rule out the histological diagnosis of PN. To reliably distinguish between PN and LS, it is necessary to correlate clinical and histological findings.<xref ref-type="bibr" rid="article-27913.r20">[20]</xref>&#x000a0;</p>
        <p>HLP and PN both demonstrate epidermal hyperplasia, hypergranulosis, and compact hyperkeratosis. Vertically arranged collagen fibers and increased fibroblasts and capillaries in the dermis are found in both conditions. However, basal cell degeneration is limited to the tips of rete ridges, and no band-like inflammation will be seen in HLP&#x000a0;versus PN<xref ref-type="bibr" rid="article-27913.r21">[21]</xref></p>
      </sec>
      <sec id="article-27913.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with PN present with characteristic firm, dome-shaped, pruritic nodules that vary from a few millimeters to a few centimeters. The nodules can be flesh-colored, erythematous, pink, and brown/black. The lesions can begin as normal skin or areas of xerosis; patients will scratch&#x000a0;them&#x000a0;due to pruritus until the dome-shaped nodule forms. Typically, the lesions are found symmetrically on the extensor surfaces of the arm and legs.<xref ref-type="bibr" rid="article-27913.r22">[22]</xref>&#x000a0;Lesions can also be found in the occipital region of the scalp. The upper back, abdomen, and sacrum also can be involved.</p>
        <p>Areas of the body that are difficult to reach, such as the upper mid-back, are usually spared from PN lesions, a finding called the &#x0201c;butterfly sign.&#x0201d; The palms, soles, face, and flexural areas are also usually spared. PN lesions cause severe pruritus,&#x000a0;which can be very distressing for patients. It can be sporadic or continuous and can increase with sweating, clothing irritation, or heat. In&#x000a0;addition to pruritic sensations, patients can experience burning, stinging, and alterations in lesional temperature.<xref ref-type="bibr" rid="article-27913.r5">[5]</xref> It has been reported that in some cases, atopic dermatitis and xerosis are found in conjunction with&#x000a0;PN and may be the initiating factor.</p>
        <p>Lesions can often appear excoriated due to the pruritus involved with PN. Excoriated lesions are at increased risk of secondary infection and can appear crusted, erythematous, or painful if infected.&#x000a0;PN can also be localized in&#x000a0;cases of underlying local dermatosis such as venous stasis, postherpetic neuralgia, or brachioradial pruritus.<xref ref-type="bibr" rid="article-27913.r23">[23]</xref></p>
      </sec>
      <sec id="article-27913.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>PN&#x000a0;is a clinical diagnosis. Patients with PN will likely have a history of chronic severe pruritus with excoriations and flesh-colored, pink nodular lesions on extensor surfaces. Dermoscopy can be a helpful tool when diagnosing PN versus HLP. In one study, dermoscopy of HLP demonstrated pearly white areas and peripheral striations, gray-blue globules, comedo-like openings, red dots and globules, brownish-black globules, and yellowish structures. In PN, red dots and globules and pearly white areas with peripheral striations were observed under dermoscopy.<xref ref-type="bibr" rid="article-27913.r24">[24]</xref>&#x000a0;A skin biopsy may be warranted for lesions that are bleeding, have formed ulcers, or are resistant to first-line therapies.</p>
        <p>In&#x000a0;patients with&#x000a0;PN and severe pruritus, underlying causes of severe pruritus should be evaluated,&#x000a0;including renal disease, liver disease, thyroid disease, HIV infection, malignancy, or parasitic infection.<xref ref-type="bibr" rid="article-27913.r25">[25]</xref>&#x000a0;Evaluation of these causes includes a complete blood cell count, complete metabolic panel, thyroid studies including&#x000a0;thyroid-stimulating hormone&#x000a0;and free thyroxine (T4), urinalysis, stool exam, HIV antibodies, and chest X-ray. Serum immunoglobulin E levels can also be elevated in patients with PN and atopic dermatitis.<xref ref-type="bibr" rid="article-27913.r26">[26]</xref></p>
      </sec>
      <sec id="article-27913.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Management of PN requires a multifaceted approach. Patients need to be educated on practices to reduce scratching of lesions. Further, any&#x000a0;psychological disorder associated with scratching and picking at skin should be diagnosed&#x000a0;and treated. Any underlying causes of pruritus should also be diagnosed. Treatments for PN, both topical and systemic, are targeted at disrupting the itch-scratch cycle.</p>
        <p>
<bold>General Care</bold>
</p>
        <p>Patients with PN should be advised to:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Keep their nails short, wear protective clothing (ie, long sleeves and gloves), and keep the nodules covered with bandages.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Bathe with&#x000a0;gentle cleansers and apply emollients&#x000a0;throughout day to keep skin moisturized.</p>
          </list-item>
          <list-item>
            <p>Use calamine lotions and lotions containing menthol and camphor&#x000a0;to&#x000a0;provide itch relief.</p>
          </list-item>
          <list-item>
            <p>Stay in a cool, comfortable environment.</p>
          </list-item>
          <list-item>
            <p>Reduce stress.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Specific Care</bold>
</p>
        <p>
<bold>Topical and Intralesional Therapy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Although none have been examined in randomized trials, topical treatments for&#x000a0;PN include class&#x000a0;I topical corticosteroids, intralesional corticosteroids, topical calcineurin inhibitors, topical capsaicin, and topical vitamin D analogs.</p>
          </list-item>
          <list-item>
            <p>The suggested first-line therapy&#x000a0;consists of&#x000a0;topical corticosteroids, such as clobetasol dipropionate 0.05% ointment, applied under occlusion with plastic wrap once at nighttime for at least&#x000a0;2 to&#x000a0;4 weeks.</p>
          </list-item>
          <list-item>
            <p>Triamcinolone acetonide, in concentrations of 10&#x000a0;mg/mL&#x000a0;to 20 mg/mL injected intralesionally, has been shown to flatten lesions and provide relief from pruritus.<xref ref-type="bibr" rid="article-27913.r27">[27]</xref><xref ref-type="bibr" rid="article-27913.r28">[28]</xref><xref ref-type="bibr" rid="article-27913.r29">[29]</xref><xref ref-type="bibr" rid="article-27913.r30">[30]</xref><xref ref-type="bibr" rid="article-27913.r31">[31]</xref></p>
          </list-item>
          <list-item>
            <p>Pimecrolimus 1% is as effective as hydrocortisone and can be implemented in a long-term regimen.<xref ref-type="bibr" rid="article-27913.r32">[32]</xref></p>
          </list-item>
          <list-item>
            <p>Calcipotriol ointment shows greater efficacy&#x000a0;than betamethasone valerate 0.1%.<xref ref-type="bibr" rid="article-27913.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>Low concentrations of menthol (&#x0003c;5%) alleviate pruritus by heightening the threshold for pruritic stimuli.<xref ref-type="bibr" rid="article-27913.r34">[34]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Antihistamines and Leukotriene Inhibitors&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>High-dose nonsedating antihistamines can be used&#x000a0;during the day, followed by first-generation sedating antihistamines at bedtime; a combination of fexofenadine and montelukast gives good results.<xref ref-type="bibr" rid="article-27913.r35">[35]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Common adverse reactions to antihistamines are drowsiness, dizziness, and weakness.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Phototherapy and Excimer Laser</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Phototherapy with psoralen&#x02013;ultraviolet-A (PUVA), including bath&#x000a0;and topical PUVA, long-wavelength UVA, narrowband UVB, and monochromatic excimer light of 308 nm, have been used and shown improvement of&#x000a0;PN nodules.</p>
          </list-item>
          <list-item>
            <p>Narrow band UVB phototherapy significantly improves PN at an average dose of 23.88-26.00 j/cm<sup>2</sup>.<xref ref-type="bibr" rid="article-27913.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>An excimer laser is more beneficial than topical clobetasol.<xref ref-type="bibr" rid="article-27913.r37">[37]</xref></p>
          </list-item>
        </list>
        <p>
<bold>&#x000a0;Oral Immunosuppressants&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>As with topical therapies, no randomized trials have been reported involving these systemic therapies, and the benefits versus risks of the drugs must be considered before beginning treatment.<xref ref-type="bibr" rid="article-27913.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Oral immunosuppressive therapy should be considered for patients with severe, recalcitrant PN.</p>
          </list-item>
          <list-item>
            <p>A single-institution retrospective study demonstrated clinical improvement and decreased pruritus with cyclosporine at a mean dose of 3.1 mg/kg.<xref ref-type="bibr" rid="article-27913.r38">[38]</xref></p>
          </list-item>
          <list-item>
            <p>Methotrexate dosed at 5 to 20 mg/kg weekly demonstrated complete or partial remission of 2.4 months. These patients showed a mean duration of response of 19 months.<xref ref-type="bibr" rid="article-27913.r39">[39]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment with azathioprine and cyclophosphamide has also been reported to be successful.<xref ref-type="bibr" rid="article-27913.r40">[40]</xref><xref ref-type="bibr" rid="article-27913.r41">[41]</xref></p>
          </list-item>
          <list-item>
            <p>Oral tacrolimus therapy dramatically reduced pruritus in a patient previously treated with cyclosporine.<xref ref-type="bibr" rid="article-27913.r42">[42]</xref></p>
          </list-item>
          <list-item>
            <p>Combination therapy of&#x000a0;3 cycles of intravenous immunoglobulin followed by methotrexate and topical steroids was effective in treating PN associated with atopic dermatitis.<xref ref-type="bibr" rid="article-27913.r43">[43]</xref></p>
          </list-item>
        </list>
        <p><bold>Novel Treatments</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Thalidomide is an immunomodulatory agent which also acts as a central and peripheral depressant and inhibits tumor necrosis factor-alpha.<xref ref-type="bibr" rid="article-27913.r43">[43]</xref> The therapeutic effect against&#x000a0;PN is thought to derive from its neurotoxic effects.<xref ref-type="bibr" rid="article-27913.r44">[44]</xref></p>
          </list-item>
          <list-item>
            <p>Lenalidomide, a more potent molecular form of thalidomide, is effective in&#x000a0;PN and has a lower frequency of peripheral neuropathy.<xref ref-type="bibr" rid="article-27913.r45">[45]</xref></p>
          </list-item>
          <list-item>
            <p>Both selective serotonin reuptake inhibitors and tricyclic antidepressants can also be considered for chronic pruritus. It is also important for patients alsbe seen in conjunction with mental health professionals.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Naloxone and naltrexone exert antipruritic effects by inhibiting Mu-opioid receptors on nociceptive neurons and interneurons, resulting in suppression of itch.<xref ref-type="bibr" rid="article-27913.r46">[46]</xref></p>
          </list-item>
          <list-item>
            <p>Neurokinin-1 receptor (NK1r) antagonists, aprepitant and serlopitant, could prevent substance P&#x02013;mediated signaling in the pathogenesis of PN.<xref ref-type="bibr" rid="article-27913.r47">[47]</xref>&#x000a0;Significant relief of itch was achieved in&#x000a0;PN patients on aprepitant monotherapy.</p>
          </list-item>
          <list-item>
            <p>IL 31 receptor antibody, nemolizumab, significantly improved pruritus scores in patients with moderate to severe atopic dermatitis; however, its role in&#x000a0;PN remains unclear.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27913.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Due to similar morphologies,&#x000a0;PN is often confused with and must be clinically separated from:</p>
        <list list-type="bullet">
          <list-item>
            <p>LS&#x000a0;chronicus&#x000a0;</p>
          </list-item>
          <list-item>
            <p>HLP</p>
          </list-item>
          <list-item>
            <p>Pemphigoid nodularis</p>
          </list-item>
          <list-item>
            <p>Nodular scabies</p>
          </list-item>
          <list-item>
            <p>Keloids</p>
          </list-item>
          <list-item>
            <p>Dermatofibroma</p>
          </list-item>
          <list-item>
            <p>Foreign body reactions</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27913.s11" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <p>Treatment of&#x000a0;PN should be tailored to a patient's age, comorbidities, severity of prurigo, quality of life, and expected side effects.</p>
        <p>
<bold>First-line Therapy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Class&#x000a0;I topical steroids:</bold>&#x000a0;Clobetasol propionate 0.05% and halobetasol propionate 0.05%); long-term applications can lead to adverse effects like skin atrophy, folliculitis, miliaria, delayed wound healing, and tachyphylaxis.</p>
          </list-item>
          <list-item>
            <p><bold>Intralesional injections:</bold>&#x000a0;Using triamcinolone acetonide (40 mg/ml); may be accompanied by cryotherapy<xref ref-type="bibr" rid="article-27913.r48">[48]</xref><xref ref-type="bibr" rid="article-27913.r49">[49]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Topical menthol solution:</bold>&#x000a0;In a concentration of less than 5%.</p>
          </list-item>
          <list-item>
            <p><bold>Systemic antihistamines:</bold>&#x000a0;Fexofenadine 180 mg, levocetirizine 5 mg, or desloratadine 5 mg during the day, and sedating antihistamines like hydroxyzine 25 mg at night time; first-generation antihistamines cause side effects like sedation, hyperexcitability, impaired cognitive function, dry mouth, constipation, dysuria, tachycardia, and arrhythmias.</p>
          </list-item>
        </list>
        <p>
<bold>Second-line Therapy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Phototherapy:</bold> PUVA, long-wavelength UVA, Narrowband UVB, monochromatic excimer light of&#x000a0;308nm</p>
          </list-item>
          <list-item>
            <p><bold>Systemic immunosuppressives:</bold> Cyclosporine 3 mg/kg daily; adverse effects include nephrotoxicity, hypertension, hyperlipidemia, hyperkalemia, and hyperuricemia. Methotrexate 5-20 mg/week; common adverse effects are nausea, gastrointestinal symptoms, and transaminitis.</p>
          </list-item>
          <list-item>
            <p><bold>Thalidomide:</bold>&#x000a0;Dosed at 300-400 mg daily yields a good response within 3 months, followed by tapering the dose to 50 mg daily; however, complete cessation of the drug leads to recurrences. Adverse effects are teratogenicity and peripheral neuropathy.</p>
          </list-item>
          <list-item>
            <p><bold>Lenalidomide:</bold>&#x000a0;Dosed at 5-10 mg daily; less neurotoxic than thalidomide.</p>
          </list-item>
          <list-item>
            <p><bold>Opioid receptor antagonists:</bold> Naltrexone 50 mg daily; adverse effects are restricted to the first 2 weeks of treatment and include nausea, fatigue, dizziness, heartburn, and diarrhea.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27913.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>PN&#x000a0;is a benign condition with a generally good prognosis. It is a chronic condition, typically preceded by an underlying cause of pruritus. However, PN is a distinct entity from&#x000a0;the underlying causes and can persist despite the resolution of the predisposing condition.&#x000a0;</p>
      </sec>
      <sec id="article-27913.s13" sec-type="Complications">
        <title>Complications</title>
        <p>PN lesions can become secondarily infected due to scratching of the lesions, leading to ulceration, abscess formation, and cellulitis. It is important to monitor for clinical signs of infection, such as erythema, pain, warmth, and fever. If secondary infection is suspected, it is important to begin appropriate topical or systemic antibiotic therapy to cover for skin flora.&#x000a0;</p>
      </sec>
      <sec id="article-27913.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>The deterrents in&#x000a0;PN treatment are the severe intensity of the itch, which can lead to psychological distress, the chronic nature of the condition, the long duration of the therapy, and the potential side effects of the medication.</p>
        <p>Discussion with the patient should include the advantages and disadvantages of the therapy, side effects, and possible use of off-label medications. Patient education can thus promote treatment adherence. The potential length of therapy should also be discussed as&#x000a0;PN is difficult to treat, and the patient may become frustrated with the lack of improvement.</p>
      </sec>
      <sec id="article-27913.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>PN&#x000a0;is a chronic skin disease that can significantly impact a patient's quality of life. Breaking the itch-scratch cycle requires a multifaceted approach, and patients should be encouraged to continue with therapy to reduce scratching and picking at the lesions. It may be necessary to involve behavioral therapy. It is important to explain to patients that PN lesions may be chronic and difficult to completely improve.</p>
      </sec>
      <sec id="article-27913.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Management of PN requires an interprofessional team that includes the primary caregiver, nurse practitioner, dermatologist, and mental health nurse. Patients need to be educated on practices to reduce scratching of lesions, assurance and diagnosing of underlying causes of pruritus, and diagnosis and treatment of any psychological disorder associated with scratching and picking at skin.</p>
        <p>Topical and systemic treatments are targeted at disrupting the itch-scratch cycle. Patients are encouraged to keep their nails short, wear protective clothing such as long sleeves and gloves, and keep the nodules covered with bandages. Using gentle cleansers to bathe and applying emollients multiple times a day to keep skin moisturized should be encouraged.</p>
        <p>Calamine lotions and lotions containing menthol and camphor-like sarna can relieve pruritus. First-generation sedating antihistamines such as hydroxyzine administered at bedtime may be useful in controlling nocturnal pruritus. Both selective serotonin reuptake inhibitors and tricyclic antidepressants can also be considered for chronic pruritus.<xref ref-type="bibr" rid="article-27913.r12">[12]</xref></p>
        <p>Finally, the pharmacist should educate the patient on potential adverse reactions to the medications and report to the clinical team if there are complications.</p>
      </sec>
      <sec id="article-27913.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27913&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27913">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/prurigo-nodularis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27913">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27913/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27913">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-27913.s18">
        <fig id="article-27913.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Prurigo Nodularis <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="prurigo__nodularis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27913.s19">
        <fig id="article-27913.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Figure 1 PRURIGO NODULARIS involving the limbs of a 65-year old lady: A, Clinical Image showing the typical hyperpigmented papules and nodules over the right upper extremity with excoriations; B, Polarized dermoscopic image from a papule showing an irregularly-shaped large reddish-brown clod with localized white structureless area (white arc), with interspersed red and brown colored dots and pigmented granules [Escope, USB Videodermoscope, 30X; Timpac Healthcare Pvt. Ltd., New Delhi]; and C, On histopathology from a nodule the epidermis is showing marked compact orthokeratosis, thickened granular layer, and irregular epidermal hyperplasia. The papillary dermis is thickened with papillomatosis and thickened bundles of collagen in vertical array, with increased number of thick walled capillaries and sparse superficial perivascular lymphocytic infiltrate [Hematoxylin &#x00026; eosin, 400X] Contributed by Dr Sidharth Sonthalia, MD, DNB, MNAMS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PN__-__Final__Picture__for__StatPearls" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27913.s20">
        <fig id="article-27913.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Prurigo Nodularis Contributed by Dr. Shyam Verma, MBBS, DVD, FRCP, FAAD, Vadodara, India</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="prurigo__nodularis__SV1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-27913.s21">
        <title>References</title>
        <ref id="article-27913.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Harbaoui</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Litaiem</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <chapter-title>Acquired Perforating Dermatosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">30969537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larson</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Stander</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kwatra</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Association between prurigo nodularis and malignancy in middle-aged adults.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>81</volume>
            <issue>5</issue>
            <fpage>1198</fpage>
            <page-range>1198-1201</page-range>
            <pub-id pub-id-type="pmid">30954580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>St&#x000e4;nder</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hirman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Perlman</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Weisshaar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Metz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luger</surname>
                <given-names>TA</given-names>
              </name>
              <collab>TCP-102 Study Group</collab>
            </person-group>
            <article-title>Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2019</year>
            <month>May</month>
            <volume>80</volume>
            <issue>5</issue>
            <fpage>1395</fpage>
            <page-range>1395-1402</page-range>
            <pub-id pub-id-type="pmid">30894279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kowalski</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Kneiber</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Valdebran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Amber</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>Treatment-resistant prurigo nodularis: challenges and solutions.</article-title>
            <source>Clin Cosmet Investig Dermatol</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>163</fpage>
            <page-range>163-172</page-range>
            <pub-id pub-id-type="pmid">30881076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iking</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grundmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chatzigeorgakidis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Phan</surname>
                <given-names>NQ</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>St&#x000e4;nder</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2013</year>
            <month>May</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>550</fpage>
            <page-range>550-7</page-range>
            <pub-id pub-id-type="pmid">22364653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rowland Payne</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>McKee</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Jurecka</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Nodular prurigo--a clinicopathological study of 46 patients.</article-title>
            <source>Br J Dermatol</source>
            <year>1985</year>
            <month>Oct</month>
            <volume>113</volume>
            <issue>4</issue>
            <fpage>431</fpage>
            <page-range>431-9</page-range>
            <pub-id pub-id-type="pmid">4063179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mattila</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Vornanen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vaara</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Katila</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Mycobacteria in prurigo nodularis: the cause or a consequence?</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>34</volume>
            <issue>2 Pt 1</issue>
            <fpage>224</fpage>
            <page-range>224-8</page-range>
            <pub-id pub-id-type="pmid">8642086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacob</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Patten</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>Strongyloides stercoralis infection presenting as generalized prurigo nodularis and lichen simplex chronicus.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>41</volume>
            <issue>2 Pt 2</issue>
            <fpage>357</fpage>
            <page-range>357-61</page-range>
            <pub-id pub-id-type="pmid">10426933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nahass</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Penneys</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>Merkel cells and prurigo nodularis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1994</year>
            <month>Jul</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>86</fpage>
            <page-range>86-8</page-range>
            <pub-id pub-id-type="pmid">7517411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaalasti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suomalainen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rechardt</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Calcitonin gene-related peptide immunoreactivity in prurigo nodularis: a comparative study with neurodermatitis circumscripta.</article-title>
            <source>Br J Dermatol</source>
            <year>1989</year>
            <month>May</month>
            <volume>120</volume>
            <issue>5</issue>
            <fpage>619</fpage>
            <page-range>619-23</page-range>
            <pub-id pub-id-type="pmid">2474315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sonkoly</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Muller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lauerma</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Pivarcsi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kemeny</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Alenius</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dieu-Nosjean</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Meller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rieker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Steinhoff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Ruzicka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zlotnik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Homey</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>IL-31: a new link between T cells and pruritus in atopic skin inflammation.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>117</volume>
            <issue>2</issue>
            <fpage>411</fpage>
            <page-range>411-7</page-range>
            <pub-id pub-id-type="pmid">16461142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boozalis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Semenov</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Stander</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kwatra</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Ethnic differences and comorbidities of 909 prurigo nodularis patients.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>79</volume>
            <issue>4</issue>
            <fpage>714</fpage>
            <page-range>714-719.e3</page-range>
            <pub-id pub-id-type="pmid">29733939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fostini</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Girolomoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tessari</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Prurigo nodularis: an update on etiopathogenesis and therapy.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>458</fpage>
            <page-range>458-62</page-range>
            <pub-id pub-id-type="pmid">23767411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanaka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aiba</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matsumura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Aoyama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tagami</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Prurigo nodularis consists of two distinct forms: early-onset atopic and late-onset non-atopic.</article-title>
            <source>Dermatology</source>
            <year>1995</year>
            <volume>190</volume>
            <issue>4</issue>
            <fpage>269</fpage>
            <page-range>269-76</page-range>
            <pub-id pub-id-type="pmid">7655104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Tey</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Extensive prurigo nodularis: characterization and etiology.</article-title>
            <source>Dermatology</source>
            <year>2014</year>
            <volume>228</volume>
            <issue>3</issue>
            <fpage>276</fpage>
            <page-range>276-80</page-range>
            <pub-id pub-id-type="pmid">24662043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Magand</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nacher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cazorla</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cambazard</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Marie</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Couppi&#x000e9;</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Predictive values of prurigo nodularis and herpes zoster for HIV infection and immunosuppression requiring HAART in French Guiana.</article-title>
            <source>Trans R Soc Trop Med Hyg</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>105</volume>
            <issue>7</issue>
            <fpage>401</fpage>
            <page-range>401-4</page-range>
            <pub-id pub-id-type="pmid">21621233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Shumack</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Prurigo nodularis: a review.</article-title>
            <source>Australas J Dermatol</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>46</volume>
            <issue>4</issue>
            <fpage>211</fpage>
            <page-range>211-18; quiz 219-20</page-range>
            <pub-id pub-id-type="pmid">16197418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pereira</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>M&#x000fc;hl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pogatzki-Zahn</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Agelopoulos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>St&#x000e4;nder</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Intraepidermal Nerve Fiber Density: Diagnostic and Therapeutic Relevance in the Management of Chronic Pruritus: a Review.</article-title>
            <source>Dermatol Ther (Heidelb)</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>509</fpage>
            <page-range>509-517</page-range>
            <pub-id pub-id-type="pmid">27730494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fukushi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Aiba</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis.</article-title>
            <source>Br J Dermatol</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>165</volume>
            <issue>5</issue>
            <fpage>990</fpage>
            <page-range>990-6</page-range>
            <pub-id pub-id-type="pmid">21711341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weigelt</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Metze</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>St&#x000e4;nder</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients.</article-title>
            <source>J Cutan Pathol</source>
            <year>2010</year>
            <month>May</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>578</fpage>
            <page-range>578-86</page-range>
            <pub-id pub-id-type="pmid">20002240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ankad</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Beergouder</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Hypertrophic lichen planus versus prurigo nodularis: a dermoscopic perspective.</article-title>
            <source>Dermatol Pract Concept</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>9</fpage>
            <page-range>9-15</page-range>
            <pub-id pub-id-type="pmid">27222766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaidya</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Prurigo nodularis: a benign dermatosis derived from a persistent pruritus.</article-title>
            <source>Acta Dermatovenerol Croat</source>
            <year>2008</year>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-44</page-range>
            <pub-id pub-id-type="pmid">18358109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pereira</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>L&#x000fc;ling</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dieckh&#x000f6;fer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Steinke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zeidler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>St&#x000e4;nder</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Brachioradial Pruritus and Notalgia Paraesthetica: A Comparative Observational Study of Clinical Presentation and Morphological Pathologies.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2018</year>
            <month>Jan</month>
            <day>12</day>
            <volume>98</volume>
            <issue>1</issue>
            <fpage>82</fpage>
            <page-range>82-88</page-range>
            <pub-id pub-id-type="pmid">28902951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nair</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Dermatoscopic Features of Prurigo Nodularis.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2019</year>
            <season>Mar-Apr</season>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>187</fpage>
            <page-range>187-189</page-range>
            <pub-id pub-id-type="pmid">30984602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nowak</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Yeung</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of pruritus.</article-title>
            <source>Can Fam Physician</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>63</volume>
            <issue>12</issue>
            <fpage>918</fpage>
            <page-range>918-924</page-range>
            <pub-id pub-id-type="pmid">29237630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Przybilla</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ring</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>V&#x000f6;lk</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Total IgE levels in the serum in dermatologic diseases].</article-title>
            <source>Hautarzt</source>
            <year>1986</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>77</fpage>
            <page-range>77-82</page-range>
            <pub-id pub-id-type="pmid">3957665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katayama</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hayashida</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sugiyama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shiohara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aoyama</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Corticosteroid-resistant prurigo nodularis: a rare syringotropic variant associated with hypohidrosis.</article-title>
            <source>Eur J Dermatol</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>212</fpage>
            <page-range>212-213</page-range>
            <pub-id pub-id-type="pmid">30827950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Legat</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>The Antipruritic Effect of Phototherapy.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2018</year>
            <volume>5</volume>
            <fpage>333</fpage>
            <pub-id pub-id-type="pmid">30560129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Pur</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Vujcic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Use of antiepileptic mood stabilizers in dermatology.</article-title>
            <source>Clin Dermatol</source>
            <year>2018</year>
            <season>Nov-Dec</season>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>756</fpage>
            <page-range>756-764</page-range>
            <pub-id pub-id-type="pmid">30446200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beck</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Sekhon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhutani</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Dupilumab Treatment for Generalized Prurigo Nodularis.</article-title>
            <source>JAMA Dermatol</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>155</volume>
            <issue>1</issue>
            <fpage>118</fpage>
            <page-range>118-120</page-range>
            <pub-id pub-id-type="pmid">30427994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qureshi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Abate</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Yosipovitch</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>A systematic review of evidence-based treatments for prurigo nodularis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>80</volume>
            <issue>3</issue>
            <fpage>756</fpage>
            <page-range>756-764</page-range>
            <pub-id pub-id-type="pmid">30261199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siepmann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lotts</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Blome</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Braeutigam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Phan</surname>
                <given-names>NQ</given-names>
              </name>
              <name>
                <surname>Butterfass-Bahloul</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Augustin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luger</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>St&#x000e4;nder</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial.</article-title>
            <source>Dermatology</source>
            <year>2013</year>
            <volume>227</volume>
            <issue>4</issue>
            <fpage>353</fpage>
            <page-range>353-60</page-range>
            <pub-id pub-id-type="pmid">24281309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Goh</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Double-blind, right/left comparison of calcipotriol ointment and betamethasone ointment in the treatment of Prurigo nodularis.</article-title>
            <source>Arch Dermatol</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>136</volume>
            <issue>6</issue>
            <fpage>807</fpage>
            <page-range>807-8</page-range>
            <pub-id pub-id-type="pmid">10871962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ishiuji</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yosipovitch</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Menthol: a refreshing look at this ancient compound.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>57</volume>
            <issue>5</issue>
            <fpage>873</fpage>
            <page-range>873-8</page-range>
            <pub-id pub-id-type="pmid">17498839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shintani</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohata</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Koga</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ohyama</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hamada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Furumura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsuruta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Combination therapy of fexofenadine and montelukast is effective in prurigo nodularis and pemphigoid nodularis.</article-title>
            <source>Dermatol Ther</source>
            <year>2014</year>
            <season>May-Jun</season>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>135</fpage>
            <page-range>135-9</page-range>
            <pub-id pub-id-type="pmid">24102897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hammes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hermann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Roos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ockenfels</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>UVB 308-nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>799</fpage>
            <page-range>799-803</page-range>
            <pub-id pub-id-type="pmid">20946583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brenninkmeijer</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Spuls</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Lindeboom</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van der Wal</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Bos</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wolkerstorfer</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Excimer laser vs. clobetasol propionate 0&#x000b7;05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot.</article-title>
            <source>Br J Dermatol</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>163</volume>
            <issue>4</issue>
            <fpage>823</fpage>
            <page-range>823-31</page-range>
            <pub-id pub-id-type="pmid">20491772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiznia</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Callahan</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Orlow</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Rapid improvement of prurigo nodularis with cyclosporine treatment.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>78</volume>
            <issue>6</issue>
            <fpage>1209</fpage>
            <page-range>1209-1211</page-range>
            <pub-id pub-id-type="pmid">29438756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klejtman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Beylot-Barry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Joly</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Debarbieux</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Misery</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wolkenstein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chosidow</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ingen-Housz-Oro</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>437</fpage>
            <page-range>437-440</page-range>
            <pub-id pub-id-type="pmid">29055135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lear</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>English</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Nodular prurigo responsive to azathioprine.</article-title>
            <source>Br J Dermatol</source>
            <year>1996</year>
            <month>Jun</month>
            <volume>134</volume>
            <issue>6</issue>
            <fpage>1151</fpage>
            <pub-id pub-id-type="pmid">8763446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Treatment of prurigo nodularis with dexamethasone-cyclophosphamide pulse therapy.</article-title>
            <source>Indian J Dermatol Venereol Leprol</source>
            <year>2016</year>
            <season>Mar-Apr</season>
            <volume>82</volume>
            <issue>2</issue>
            <fpage>239</fpage>
            <pub-id pub-id-type="pmid">26924412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halvorsen</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Aaseb&#x000f8;</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Oral tacrolimus treatment of pruritus in prurigo nodularis.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>95</volume>
            <issue>7</issue>
            <fpage>866</fpage>
            <page-range>866-7</page-range>
            <pub-id pub-id-type="pmid">25804254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feldmeyer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Werner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kamarashev</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Hofbauer</surname>
                <given-names>GF</given-names>
              </name>
            </person-group>
            <article-title>Atopic prurigo nodularis responds to intravenous immunoglobulins.</article-title>
            <source>Br J Dermatol</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>166</volume>
            <issue>2</issue>
            <fpage>461</fpage>
            <page-range>461-2</page-range>
            <pub-id pub-id-type="pmid">21910702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Innovative uses of thalidomide.</article-title>
            <source>Dermatol Clin</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>577</fpage>
            <page-range>577-86</page-range>
            <pub-id pub-id-type="pmid">20510766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanavy</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bahner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Korman</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Treatment of refractory prurigo nodularis with lenalidomide.</article-title>
            <source>Arch Dermatol</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>148</volume>
            <issue>7</issue>
            <fpage>794</fpage>
            <page-range>794-6</page-range>
            <pub-id pub-id-type="pmid">22801610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phan</surname>
                <given-names>NQ</given-names>
              </name>
              <name>
                <surname>Lotts</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Antal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bernhard</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>St&#x000e4;nder</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>92</volume>
            <issue>5</issue>
            <fpage>555</fpage>
            <page-range>555-60</page-range>
            <pub-id pub-id-type="pmid">22504709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Capellino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Phan</surname>
                <given-names>NQ</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luger</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Straub</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>St&#x000e4;nder</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis.</article-title>
            <source>J Dermatol Sci</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>193</fpage>
            <page-range>193-7</page-range>
            <pub-id pub-id-type="pmid">20417061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waldinger</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Voorhees</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Cryotherapy improves prurigo nodularis.</article-title>
            <source>Arch Dermatol</source>
            <year>1984</year>
            <month>Dec</month>
            <volume>120</volume>
            <issue>12</issue>
            <fpage>1598</fpage>
            <page-range>1598-600</page-range>
            <pub-id pub-id-type="pmid">6508332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27913.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stoll</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Fields</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Treatment of prurigo nodularis: use of cryosurgery and intralesional steroids plus lidocaine.</article-title>
            <source>J Dermatol Surg Oncol</source>
            <year>1983</year>
            <month>Nov</month>
            <volume>9</volume>
            <issue>11</issue>
            <fpage>922</fpage>
            <page-range>922-4</page-range>
            <pub-id pub-id-type="pmid">6630706</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
